Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed lung cancer (Stage IIIb/IV nonsmall-cell lung cancer or extensive stage small-cell lung cancer \[SCLC\])~* Measurable tumor lesion (as long as it is not located in a previously irradiated area) as defined by modified World Health Organization criteria~* Eastern Cooperative Oncology Group performance status of ≤1 at study entry~* Accessible for treatment and follow-up~Exclusion Criteria:~* Brain metastases~* Malignant pleural effusion~* Autoimmune disease~* Motor neuropathy of autoimmune origin~* SCLC-related paraneoplastic syndromes~* Any concurrent malignancy other than nonmelanoma skin cancer; carcinoma in situ of the cervix or breast; or prostate cancer treated with systemic therapy (participants with a previous malignancy but without evidence of disease for 5 years were allowed to enter the study)~* Prior systemic therapy for lung cancer. Prior radiation therapy or locoregional surgeries performed later than at least 3 weeks prior to randomization date were allowed.~  * Grade 2 peripheral neuropathy (motor or sensory)~* Known HIV or hepatitis B or C infection~* Chronic use of immunosuppressants and/or systemic corticosteroids (used in the management of cancer or noncancer-related illnesses). However, use of corticosteroids was allowed if used as premedication for paclitaxel infusion or for treating immune-related adverse events or adrenal insufficiencies.~* Inadequate hematologic function defined by an absolute neutrophil count \<1,500/mm\^3, a platelet count \<100,000/mm\^3, or hemoglobin level \<9 g/dL.~* Inadequate hepatic function defined by a total bilirubin level \>2.0 times the upper limit of normal (ULN), or ≥2.5 times the ULN if liver metastases are present, aspartate aminotransferase and alanine aminotransferase levels ≥2.5 times the ULN or ≥5 times the ULN if liver metastases are present.~* Inadequate renal function defined by a serum creatinine level ≥2.5 times the ULN~* Inadequate creatinine clearance defined as less than 50 mL/min.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ipilimumab/ placebo + paclitaxel + carboplatin (concurrent) (Type: EXPERIMENTAL): None
- Ipilimumab/ placebo + paclitaxel + carboplatin (sequential) (Type: EXPERIMENTAL): None
- Ipilimumab placebo + paclitaxel + carboplatin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).